Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

Vaccine

Volumn 22, Issue 21-22, 2004, Pages 2943-2952

  Fife, Kenneth H ^a   Wheeler, Cosette M ^b   Koutsky, Laura A ^c   Barr, Eliav ^d   Brown, Darron R ^a,e   Schiff, Melissa A ^b   Kiviat, Nancy B ^c   Jansen, Kathrin U ^d   Barber, Harriet ^b   Smith, Judith F ^d   Tadesse, Amha ^d   Giacoletti, Katherine ^d   Smith, Paula R ^d   Suhr, Gretchen ^d   Johnson, Daniel A ^d  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cervical intraepithelial neoplasia; Condyloma acuminata; Controlled trials; Viral vaccines

Indexed keywords

ANTIBODY; CAPSID PROTEIN; HUMAN PAPILLOMAVIRUS TYPE 11 VIRUS LIKE PARTICLE VACCINE; HUMAN PAPILLOMAVIRUS TYPE 16 VIRUS LIKE PARTICLE VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; HEALTH STATUS; HUMAN; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; PAIN; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CAPSID PROTEINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; VIRAL VACCINES;

EID: 3142604951     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.058     Document Type: Article

References (42)

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102:1997;3-8
2. Cates W. Jr. American Social Health Association Panel: estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm. Dis. 26:1999;S2-S7
3. Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D.M., Rush B.B., et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 85:1993;958-964
4. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:1995;796-802
5. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19
6. Pisani P., Parkin D.M., Munoz N., Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 6:1997;387-400
7. Beutner K.R., Wiley D.J., Douglas J.M., Tyring S.K., Fife K., Trofatter K., et al. Genital warts and their treatment. Clin. Infect. Dis. 28:1999;S37-S56
8. National Cancer Institute. Surveillance Epidemiology and End-Results. Department of Health and Human Services, Washington, DC; 2000.
9. Eddy D.M. Screening for cervical cancer. Ann. Intern. Med. 113:1990;214-226
10. Mandelblatt J.S., Lawrence W.F., Womack S.M., Jacobson D., Yi B., Hwang Y.T., et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 287:2002;2372-2381
11. Bar-Am A., Daniel Y., Ron I.G., Niv J., Kupfermiac M.J., Bornstein J., et al. Combined colposcopy, loop conization, and laser vaporization reduces recurrent abnormal cytology and residual disease in cervical dysplasia. Gynecol. Oncol. 78:2000;47-51
12. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly fo HPV virion-like particles. Virology. 185:1991;251-257
13. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U.S.A. 89:1992;12180-12184
14. Rose R.C., Bonnez W., Reichman R.C., Garcea R.L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus-like particles. J. Virol. 67:1993;1936-1944
15. Lowe R.S., Brown D.R., Bryan J.T., Cook J.C., George H.A., Hofmann K.J., et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis. 176:1997;1141-1145
16. Hagensee M.E., Olson N.H., Baker T.S., Galloway D.A. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J. Virol. 68:1994;4503-4505
17. Jansen K.U., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J., et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 13:1995;1509-1514
18. Breitburd F., Kirnbauer R., Hubbert N.L., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:1995;3959-3963
19. Christensen N.D., Reed C.A., Cladel N.M., Han R., Kreider J.W. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Virol. 70:1996;960-965
20. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 219:1996;37-44
21. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U.S.A. 92:1995;11553-11557
22. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:2003;518-527
23. ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
24. Gissmann L., zur Hausen H. Partial characterization of viral DNA from human genital warts (Condylomata acuminata). Int J Cancer. 25:1980;605-609
25. de Villiers E.-M., Gissmann L., Hausen H. Molecular cloning of viral DNA from human genital warts. J. Virol. 40:1981;932-935
26. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:2002;1645-1651
27. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:2001;284-292
28. Evans T.G., Bonnez W., Rose R.C., Koenig S., Demeter L., Suzich J.A., et al. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183:2001;1485-1493
29. Palker T.J., Monteiro J.M., Martin M.M., Kakareka C., Smith J.F., Cook J.C., et al. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine. 19:2001;3733-3743
30. O'Connell M, Belanger B, Haaland P. The four-parameter logistic model for calibration and assay development. Am Stat Assoc Proc Biopharm Section 1992:180-85.
31. Carter J.J., Koutsky L.A., Hughes J.P., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181:2000;1911-1919
32. Tukey J.W., Ciminera J.L., Heyse J.F. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 41:1985;295-301
33. Miettinen O., Nurminen M. Comparative analysis of two rates. Stat. Med. 4:1985;213-226
34. Brown D.R., Bryan J.T., Schroeder J.M., et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J. Infect. Dis. 184:2001;1183-1186
35. Christensen N.D., Kreider J.W., Shah K.V., Rando R.F. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J. Gen. Virol. 73:1992;1261-1267
36. Bonnez W., Rose R.C., Reichman R.C. Antibody-mediated neutralization of human papillomavirus type 11 (HPV 11) infection in the nude mouse: detection of HPV-11 mRNAs. J. Infect. Dis. 165:1992;376-380
37. Rose R.C., Reichman R.C., Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J. Gen. Virol. 75:1994;2075-2079
38. Smith L.H., Foster C., Hitchcock M.E., Leiserowitz B.S., Hall K., Isseroff R., et al. Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J. Invest. Dermatol. 105:1995;438-444
39. Bryan J.T., Jansen K.U., Lowe R.S., Fife K.H., McClowry T., Glass D., et al. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration. J. Med. Virol. 53:1997;185-188
40. Goilav C., Zuckerman J., Lafrenz M., Vidor E., Lauwers S., Ratheau C., et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J. Med. Virol. 46:1995;287-292
41. Langenberg A.G.M., Burke R.L., Adair S.F., Sekulich R., Tigges M., Dekker C.L., et al. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Ann. Intern. Med. 122:1995;889-898
42. Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R, et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 2004;22(21-22):2936-42.